Paradigm Biopharmaceuticals (PBIGF) Price & Analysis

Compare

17 Followers

PBIGF Stock Chart & Stats

$0.24

-$0.01(-3.72%)

At close: Jan 06 4:00 PM EST

$0.24

-$0.01(-3.72%)

Day’s Range― - ―

52-Week Range$0.13 - $0.35

Previous CloseN/A

Volume2.27K

Average Volume (3M)1.65K

Market Cap

$77.61M

Enterprise Value$96.16M

Total Cash (Recent Filing)$14.66M

Total Debt (Recent Filing)$1.01M

Price to Earnings (P/E)―

Beta-0.32

Next Earnings

Aug 28, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.04

Shares Outstanding439,254,430

10 Day Avg. Volume200

30 Day Avg. Volume1,650

Financial Highlights & Ratios

PEG Ratio0.07

Price to Book (P/B)4.53

Price to Sales (P/S)1840.42

P/FCF Ratio-6.00

Enterprise Value/Market Cap1.24

Enterprise Value/Revenue1.59K

Enterprise Value/Gross Profit-985.53

Enterprise Value/Ebitda-2.36

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.07

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Low Leverage / Refinancing RiskVery low debt reduces refinancing and interest-rate risk, preserving financial optionality for a biotech development cycle. This structural strength lengthens runway and improves the company's ability to fund R&D or clinical milestones without urgent debt maturities over the next several months.

Improving Cash Burn And Loss ProfileA materially narrower net loss and sharply reduced cash outflow in FY2025 signal operational progress and tighter cost control. That persistent improvement, if sustained, lowers near-term financing needs and increases the chance of achieving milestone-based funding or breakeven over a 2–6 month horizon.

Structural Offset To Weak ResultsThe combination of conservative leverage and an improving FY2025 loss/burn profile creates a durable buffer versus cyclical stresses. This structural offset supports continued R&D progress and provides management time to execute strategic priorities without immediate capital distress.

Bears Say

Minimal And Volatile RevenueVery small, volatile and declining revenue undermines scale economics and makes long-term business self-sustainability unlikely. Persistent top-line weakness limits reinvestment capacity, weakens pricing leverage and hampers margin recovery absent structural revenue growth or new commercial milestones.

Consistent Negative Cash GenerationChronic negative operating and free cash flow means the business relies on external financing to continue operations. That structural cash burn elevates dilution and execution risk, constraining strategic choices and making long-term project funding contingent on capital markets access.

Declining Equity And Negative ROEMaterial declines in shareholder equity and persistently negative ROE signify cumulative losses and value erosion. This structural deterioration undermines investor confidence, can limit future fundraising options, and reflects an ongoing inability to generate shareholder returns from operations.

Paradigm Biopharmaceuticals News

Paradigm Biopharmaceuticals Widens Half-Year Loss on Intensified Phase 3 Investment

Paradigm Biopharmaceuticals ( ($AU:PAR) ) has provided an update. Paradigm Biopharmaceuticals reported a net loss before tax of...

7d ago

Paradigm Biopharmaceuticals Updates Market on Director Paul Rennie’s Equity Holdings

Paradigm Biopharmaceuticals ( ($AU:PAR) ) has shared an update. Paradigm Biopharmaceuticals has disclosed changes in director Paul Rennie’s...

11d ago

Paradigm Biopharmaceuticals Updates Market on Director Option Lapse

The latest update is out from Paradigm Biopharmaceuticals ( ($AU:PAR) ). Paradigm Biopharmaceuticals has disclosed a change in...

11d ago

Paradigm’s PPS Shows Sustained Clinical and Structural Benefits in Canine Osteoarthritis Study

Paradigm Biopharmaceuticals ( ($AU:PAR) ) has issued an announcement. Paradigm Biopharmaceuticals announced that a Paradigm-supported study of pentosan...

23d ago

Paradigm Strikes AVet Licensing Deal for Novel Oral Veterinary Osteoarthritis Drug

Paradigm Biopharmaceuticals ( ($AU:PAR) ) just unveiled an update. Paradigm Biopharmaceuticals has signed a binding term sheet with...

25d ago

Paradigm Biopharmaceuticals Director Converts Options Into Shares

Paradigm Biopharmaceuticals ( ($AU:PAR) ) has issued an update. Paradigm Biopharmaceuticals has disclosed a change in the interests...

1M ago

Paradigm Biopharmaceuticals Seeks ASX Quotation for Additional Ordinary Shares

Paradigm Biopharmaceuticals ( ($AU:PAR) ) has provided an update. Paradigm Biopharmaceuticals has applied to the ASX for quotation...

1M ago

Paradigm Biopharmaceuticals Seeks ASX Quotation for Additional Ordinary Shares

Paradigm Biopharmaceuticals ( ($AU:PAR) ) has shared an update. Paradigm Biopharmaceuticals has applied for quotation on the ASX...

1M ago

Paradigm Expands Global Phase 3 Knee Osteoarthritis Trial as Peer-Reviewed Data Bolster iPPS Case

Paradigm Biopharmaceuticals ( ($AU:PAR) ) just unveiled an announcement. Paradigm Biopharmaceuticals reported continued operational progress in the December...

1M ago

Paradigm Biopharmaceuticals Seeks ASX Quotation for Additional Ordinary Shares

Paradigm Biopharmaceuticals ( ($AU:PAR) ) has provided an update. Paradigm Biopharmaceuticals has applied for quotation on the ASX...

1M ago

PBIGF FAQ

What was Paradigm Biopharmaceuticals Ltd.’s price range in the past 12 months?

Paradigm Biopharmaceuticals Ltd. lowest stock price was $0.13 and its highest was $0.35 in the past 12 months.

What is Paradigm Biopharmaceuticals Ltd.’s market cap?

Paradigm Biopharmaceuticals Ltd.’s market cap is $77.61M.

When is Paradigm Biopharmaceuticals Ltd.’s upcoming earnings report date?

Paradigm Biopharmaceuticals Ltd.’s upcoming earnings report date is Aug 28, 2026 which is in 175 days.

How were Paradigm Biopharmaceuticals Ltd.’s earnings last quarter?

Paradigm Biopharmaceuticals Ltd. released its earnings results on Feb 25, 2026. The company reported -$0.04 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.04.

Is Paradigm Biopharmaceuticals Ltd. overvalued?

According to Wall Street analysts Paradigm Biopharmaceuticals Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Paradigm Biopharmaceuticals Ltd. pay dividends?

Paradigm Biopharmaceuticals Ltd. does not currently pay dividends.

What is Paradigm Biopharmaceuticals Ltd.’s EPS estimate?

Paradigm Biopharmaceuticals Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Paradigm Biopharmaceuticals Ltd. have?

Paradigm Biopharmaceuticals Ltd. has 439,254,430 shares outstanding.

What happened to Paradigm Biopharmaceuticals Ltd.’s price movement after its last earnings report?

Paradigm Biopharmaceuticals Ltd. reported an EPS of -$0.04 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Paradigm Biopharmaceuticals Ltd.?

Currently, no hedge funds are holding shares in PBIGF

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Paradigm Biopharmaceuticals Stock Smart Score

Neutral

Blogger Sentiment

Bullish

PBIGF Sentiment 90%
Sector Average ―

Technicals

Fundamentals

Return on Equity

-81.03%

Trailing 12-Months

Asset Growth

-11.97%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Paradigm Biopharmaceuticals Ltd.

Paradigm Biopharmaceuticals Limited, a drug repurposing company, engages in the research and development of therapeutic products for human use in Australia. It offers pentosan polysulfate sodium drugs in the injectable form for the treatment of osteoarthritis, mucopolysaccharidosis, ross river virus, chikungunya virus, and acute respiratory distress syndrome diseases. The company was incorporated in 2014 and is based in Melbourne, Australia.